UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 19, 2016
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S
Employer
Identification No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
[ ] |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
[ ] |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
7.01 Regulation FD Disclosure
On
January 19, 2016, RespireRx Pharmaceuticals Inc. (the “Company”) announced that the Company’s Vice President,
Treasurer and Secretary and member of the Board of Directors, Jeff Margolis will present at the Noble Financial Capital Markets’
Twelfth Annual Investor/Equity Conference – NobleCon12 on Wednesday, January 20, 2016 at 10:30 AM Eastern Standard Time.
The Conference is sponsored by Noble Financial Capital Markets and will be held at the Sandpiper Bay Club Med facility in Port
St. Lucie, Florida from January 17 – 20, 2016.
The
slide presentation that the Company will be using at the conference is attached as Exhibit 99.1 and is being furnished and not
filed pursuant to Item 7.01 of Form 8-K. The presentation will be available by live webcast that can be accessed by clicking on
the investors tab on the Company’s web-site (www.respirerx.com) and following the links and instructions or by going to:
http://noble.mediasite.com/mediasite/Play/2fffb581d269487ca511a4cb740447051d.
The
press release announcing the Company’s participation in the conference is attached as Exhibit 99.2.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits that are furnished and filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
RESPIRERX
PHARMACEUTICALS INC. |
Date:
January 19, 2016 |
|
|
|
|
|
By: |
/s/
James S. J. Manuso |
|
|
James
S. J. Manuso
President
and Chief Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
|
Exhibit
Description |
|
|
|
99.1 |
|
Slide
Presentation* |
|
|
|
99.2 |
|
Press
Release dated January 19, 2016* |
*
Furnished herewith.
RespireRx
Pharmaceuticals Inc. to Present at Noble Financial Capital Markets’ Twelfth Annual Investor/Equity Conference – NobleCon12
Glen
Rock, N.J., January 19, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or
the “Company”), a leader in developing drugs for respiratory disorders, particularly sleep apneas and drug-induced
respiratory depression, announces that the Company’s Vice President, Treasurer and Secretary and member of the Board of
Directors, Jeff Margolis will present at the Noble Financial Capital Markets’ Twelfth Annual Investor/Equity Conference
– NobleCon12 on Wednesday, January 20, 2016 at 10:30 AM Eastern Standard Time (http://nobleconference.com/general-agenda).
The Conference is sponsored by Noble Financial Capital Markets and will be held at the Sandpiper Bay Club Med facility in Port
St. Lucie, Florida from January 17 – 20, 2016.
Mr.
Margolis will discuss RespireRx’s initiatives with dronabinol for obstructive sleep apnea (Phase - 2B), CX-1739 (oral) for
drug-induced respiratory depression and central sleep apnea (both Phase - 2A). He will also provide background information and
descriptions of other product pipeline candidates.
Mr.
Margolis’ presentation will be available by live webcast streaming online and will also be archived. To access the live
audio webcast, log onto the RespireRx website at www.respirerx.com, click on the investors tab and follow the links and instructions,
or go to http://noble.mediasite.com/mediasite/Play/2fffb581d269487ca511a4cb740447051d. A copy of the slide presentation
to be presented at the conference will be submitted in a filing by the Company with the U.S. Securities and Exchange Commission
in a Current Report on Form 8-K prior to the presentation and will also be available in the investors section of the RespireRx
website.
Comments
by the Company’s Vice President, Treasurer and Secretary
Jeff
Margolis, RespireRx Vice President, Treasresurer and Secretary, commented, “We are looking forward to the opportunity to present
our strategic and operational goals for 2016 at the upcoming Noble Conference. Management will continue to update shareholders
and other stakeholders on the progress of RespireRx’s scientific, clinical and regulatory development initiatives during
2016.”
About
RespireRx Pharmaceuticals Inc.
RespireRx
Pharmaceuticals Inc. is a leader in the development of drugs for respiratory disorders, with a focus on sleep apneas and
drug-induced respiratory depression. The Company holds exclusive licenses and owns patents and patent applications for certain
families of chemical compounds that claim the chemical structures and their use in the treatment of a variety of disorders, as
well as claims for novel uses of known drugs.
RespireRx
Pharmaceuticals Inc., 126 Valley Road, Suite C, Glen Rock, NJ 07452
www.RespireRx.com
RespireRx’s
pharmaceutical candidates in development are derived from two platforms, as described below.
The
first platform is the class of compounds known as cannabinoids, in particular, dronabinol. Under a license agreement with the
University of Illinois, the Company has rights to patents claiming the use of cannabinoids for the treatment of sleep-related
breathing disorders. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol
produced a statistically significant reduction in the Apnea-Hypopnea Index, the primary therapeutic end-point, and was observed
to be safe and well-tolerated in a group of patients with Obstructive Sleep Apnea (“OSA”). The University of Illinois
and three other centers currently are investigating dronabinol in a potentially pivotal, six week, double-blind, placebo-controlled
Phase 2B clinical trial in 120 patients with OSA. This study, which the University of Illinois has indicated it expects to be
completed during the second quarter of 2016, is fully funded by the National Heart, Lung and Blood Institute of the National Institutes
of Health. The Company is not managing or funding this ongoing clinical trial.
The
second platform of medicines being developed by RespireRx is a class of proprietary compounds known as ampakines, which act to
enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors. Several ampakines, in both oral
and injectable form, are being developed by the Company for the treatment of a variety of breathing disorders. In clinical studies,
select ampakines have shown preliminary efficacy in central sleep apnea and in the control of respiratory depression produced
by opiates, without altering their analgesic effects. In animal models of orphan disorders, such as Pompé Disease, spinal
cord damage and perinatal respiratory distress, it has been demonstrated that certain ampakines improve breathing function. The
Company’s compounds belong to a new class of ampakines that do not display the undesirable side effects previously reported
in animal models of earlier generations.
Additional
information about the Company and the matters discussed herein can be obtained on the Company’s web-site at www.RespireRx.com
or in the Company’s filings with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov.
Special
Note Regarding Forward-Looking Statements: Certain statements included or incorporated by reference in this news release,
including information as to the future financial or operating performance of the Company and its drug development programs, constitute
forward-looking statements. The words “believe,” “expect,” “anticipate,” “contemplate,”
“target,” “plan,” “intend,” “continue,” “budget,” “estimate,”
“may,” “schedule” and similar expressions identify forward-looking statements. Forward-looking statements
include, among other things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements
are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently
subject to significant business, economic and competitive uncertainties and contingencies. Many factors could cause the Company’s
actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of,
the Company. Due to these various risks and uncertainties, actual events may differ materially from current expectations. Investors
are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned
not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Forward-looking statements are
made as of the date of this news release and the Company disclaims any intent or obligation to update publicly such forward-looking
statements, whether as a result of new information, future events or results or otherwise.
Company
Contact:
Jeff
Margolis
Vice-President, Treasurer and Secretary
Telephone:
(917) 834-7206
E-mail: jmargolis@respirerx.com
RespireRx
Pharmaceuticals Inc., 126 Valley Road, Suite C, Glen Rock, NJ 07452
www.RespireRx.com
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Aug 2024 to Sep 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Sep 2023 to Sep 2024